Research study · Cureus · 2026
Water-Dispersible Palmitoylethanolamide (PEA) Supplementation for Functional Improvement in Adults With Chronic Sciatica-Related Back Pain: A Pilot Clinical Trial
Verified on PubMed Oxford CEBM Level 1B: Randomized Controlled Trial
A 2026 clinical trial in Cureus tested palmitoylethanolamide in pain. The results were encouraging, but this study cannot prove the supplement works. This study shows that a supplement of this kind was followed by a fall in pain and leg-nerve symptoms over four weeks, without reported side effects in a small group that all knew.
In plain language
Study overview
Sixty adults with long-lasting lower back pain that runs down into the leg were given a daily powdered supplement for four weeks. The supplement combined a fatty compound called palmitoylethanolamide with an extract from a flowering plant. Everyone knew they were taking it, and there was no comparison group receiving a dummy product.
Findings
The results were encouraging, but this study cannot prove the supplement works. Pain scores dropped steadily, and people reported less shooting, tingling and numbness, with no side effects reported.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Background: Chronic low back pain (LBP) with sciatica is a major public health problem; nutraceuticals are used as adjuncts, but evidence is heterogeneous. Palmitoylethanolamide (PEA) and Acmella oleracea extract have been studied individually; combined evidence is limited. Methods: Open-label, single-center, prospective pilot trial over 4 weeks of a nutraceutical combination of PEA (90%) and Acmella oleracea flower extract (1.5%) with functional excipients (8.5%), given as one 670 mg sachet daily. Pain was measured with the Numeric Rating Scale (NRS) and neuropathic features with the Douleur Neuropathique 4 (DN4) questionnaire; daily living function and safety were also assessed. Results: Sixty participants were enrolled and all completed the study. Mean NRS fell from 5.12 at baseline to 1.65 at week 4 (p<0.001), with a significant reduction by day 3 and all participants below NRS 4 at week 4. Median DN4 fell from 6.0 to 1.0 (p<0.001). Functional total score improved significantly (Friedman test, p<0.001). No adverse events or significant laboratory changes were reported. Conclusions: Preliminary evidence suggests a safe and potentially effective approach with rapid onset in chronic LBP with neuropathic features; randomized controlled trials are needed.
The paper
Citation
Raju HN, Subramanian D, Russo R Water-Dispersible Palmitoylethanolamide (PEA) Supplementation for Functional Improvement in Adults With Chronic Sciatica-Related Back Pain: A Pilot Clinical Trial. Cureus (2026). PubMed 42255791 · DOI
Read the abstract as published
Background Chronic pain, including low back pain (LBP), represents a major global public health issue and significantly affects quality of life. Low back pain is a highly prevalent condition worldwide and remains a growing public health concern. Current conventional management includes pharmacological approaches such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and muscle relaxants, as well as non-pharmacological interventions including physical therapy and physiotherapy. Nutraceuticals are increasingly used as an adjunctive strategy, particularly in patients intolerant to conventional pharmacological treatments or requiring long-term management. Although some evidence supports their potential benefit, the overall quality of clinical data remains heterogeneous, and further well-designed studies are needed to establish efficacy and optimal use. Among these, palmitoylethanolamide (PEA) and botanical extracts such as Acmella oleracea have been individually investigated; however, evidence regarding their combined use remains limited and insufficiently explored. Methods This pilot, open-label clinical trial evaluated the effects of a novel nutraceutical combination containing PEA and Acmella oleracea extract in subjects with low back pain with sciatica over a 4-week period. Pain intensity was assessed using the Numeric Rating Scale (NRS), while pain characteristics were evaluated using the validated Douleur Neuropathique 4 (DN4) questionnaire. The impact on daily living activities, as well as safety and tolerability, was also investigated. Results Sixty participants were recruited. Baseline NRS score was 5.12±0.79 and showed a significant reduction as early as 3 days after supplementation, with continued improvement throughout the study period, reaching 1.65 ± 0.66 at the end of the study (p<0.001). DN4 scores also decreased significantly over time, with reductions observed across most neuropathic pain descriptors. Improvements in daily functioning were similarly significant. The nutraceutical combination was well tolerated, with no relevant adverse events reported. Conclusions Although preliminary, these findings suggest that the investigated nutraceutical combination may represent a safe and potentially effective approach with a relatively rapid onset of action for the management of chronic low back pain with neuropathic features, including sciatica. Further randomized, controlled studies are warranted to confirm these results and to better define the clinical role of this approach.
Abstract text as indexed by PubMed for this identifier.
Limitations the authors noted
Open-label, uncontrolled single-arm design; no placebo or comparator group, so placebo effect and regression to the mean cannot be excluded. Self-reported outcomes and very high PGIC responder rate (100%) may overstate effects. Functional questionnaire was investigator-administered and not validated. No long-term follow-up beyond 4 weeks; durability after discontinuation unknown. No formal sample size calculation; pilot scope; no MRI or psychosocial screening (STarT Back). Sponsor-affiliated authors and sponsor funding (Giellepi S.p.A.) with patented product; potential bias. Single center and single population; generalizability limited.
In practice
Why this matters
This study shows that a supplement of this kind was followed by a fall in pain and leg-nerve symptoms over four weeks, without reported side effects in a small group that all knew they were taking it. It does not show that the supplement caused the improvement, because there was no comparison group and the study was paid for by the company that makes the product. A reader should treat it as a reason to run a properly controlled trial, and it leaves open whether the results hold over longer periods or in other groups of patients.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Palmitoylethanolamide and Adverse events?
The results were encouraging, but this study cannot prove the supplement works. Pain scores dropped steadily, and people reported less shooting, tingling and numbness, with no side effects reported.
What study limitations or clinical safeguards should patients keep in mind?
Open-label, uncontrolled single-arm design; no placebo or comparator group, so placebo effect and regression to the mean cannot be excluded. Self-reported outcomes and very high PGIC responder rate (100%) may overstate effects. Functional questionnaire was investigator-administered and not...
Browse related research
Condition: Adverse events Condition: Low back pain Condition: Pain Topic: Palmitoylethanolamide
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 22, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
